Percheron Therapeutics Limited has released a press release.
AGM Presentation 2019
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
In the deck
Earlier from Percheron Therapeutics
- Dosing completed in ATL1102 Phase II DMD trial
- Appendix 4C - quarterly
- Response to ASX Price Query
- Positive preliminary results from ATL1102 DMD Phase II trial
- ATL1102 for DMD European regulatory interactions
Later from Percheron Therapeutics
- Suspension from Official Quotation
- Positive results reaffirm plans to advance ATL1102 to P2b
- Antisense Therapeutics Limited - Listed Options raise $5.5M
- Quarterly Update & Appendix 4C
- Results in DMD unlock value creation potential of ATL1102
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics